Enhanced Discrimination of Malignant from Benign Pancreatic Disease by Measuring the CA 19-9 Antigen on Specific Protein Carriers

Tingting Yue, Kevin A. Maupin, Brian P. Fallon, +11

PLoS ONE

Specific Protein CarriersOncologyPancreatic CancerPancreatic Fluid CollectionMedicine +13

Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases

Tingting Yue, Katie Partyka, Kevin A. Maupin, +7

PROTEOMICS

Pancreatic DiseasesPrognostic BiomarkersPancreatic CancerMedicineProteomics +13

MicroRNA-26a Is Strongly Downregulated in Melanoma and Induces Cell Death through Repression of Silencer of Death Domains (SODD)

Steven N. Reuland, Shilo M. Smith, Lynne Bemis, +7

Journal of Investigative Dermatology

Tumor BiologyMedicineMelanomaDeath DomainsCell Death +10

Diverse monoclonal antibodies against the <scp>CA</scp> 19‐9 antigen show variation in binding specificity with consequences for clinical interpretation

Katie Partyka, Kevin A. Maupin, Randall E. Brand, +1

PROTEOMICS

Clinical ImmunologyImmunocytochemical TechniqueClinical InterpretationImmunologyPathology +17

The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis

Ben Staal, Ying Liu, Daniel Barnett, +10

Clinical Cancer Research

Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens

Brian B. Haab, Ying Huang, Seetharaman Balasenthil, +19

PLoS ONE

Glycan Motif Profiling Reveals Plasma Sialyl-Lewis X Elevations in Pancreatic Cancers That Are Negative for Sialyl-Lewis A *

Huiyuan Tang, Sudhir Kumar Singh, Katie Partyka, +10

Molecular & Cellular Proteomics

GlycobiologyPathologyPlasma SleaCancer BiologyTumor Biology +17

Glycans Related to the CA19-9 Antigen Are Increased in Distinct Subsets of Pancreatic Cancers and Improve Diagnostic Accuracy Over CA19-9

Huiyuan Tang, Katie Partyka, Peter Hsueh, +6

Cellular and Molecular Gastroenterology and Hepatology

ABT-737 synergizes with Bortezomib to kill melanoma cells

Steven N. Reuland, Nathaniel B. Goldstein, Katie Partyka, +7

Biology Open

Noxa ExpressionMedicineApoptosisPharmacologyImmunology +13

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53

Steven N. Reuland, Nathaniel B. Goldstein, Katie Partyka, +4

PLoS ONE

Cell DeathCancer BiologyTumor BiologyAnti-cancer AgentMelanoma Cells Independent +14